Any feedback?
Literature summary for 3.4.14.5 extracted from
- GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors (2007), Curr. Diab. Rep., 7, 340-347.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | glucagon-like peptide-1-based therapy is a treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A1c by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| sitagliptin | - |
Homo sapiens |  |
| vildagliptin | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| glucagon-like peptide-1 + H2O | - |
Homo sapiens | ? | - |
? | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
